Evolution of hepatitis B serological markers in HIV coinfected patients: a case study

ABSTRACT OBJECTIVE To describe the evolution of serological markers among HIV and hepatitis B coinfected patients, with emphasis on evaluating the reactivation or seroreversion of these markers. METHODS The study population consisted of patients met in an AIDS Outpatient Clinic in São Paulo Stat...

Full description

Bibliographic Details
Main Authors: Ana Luiza de Castro Conde Toscano, Maria Cássia Mendes Corrêa
Format: Article
Language:English
Published: Universidade de São Paulo
Series:Revista de Saúde Pública
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102017000100219&lng=en&tlng=en
id doaj-160d4555454e4432a85aefbefceec121
record_format Article
spelling doaj-160d4555454e4432a85aefbefceec1212020-11-24T23:50:56ZengUniversidade de São PauloRevista de Saúde Pública1518-878751010.1590/s1518-8787.2017051006693S0034-89102017000100219Evolution of hepatitis B serological markers in HIV coinfected patients: a case studyAna Luiza de Castro Conde ToscanoMaria Cássia Mendes CorrêaABSTRACT OBJECTIVE To describe the evolution of serological markers among HIV and hepatitis B coinfected patients, with emphasis on evaluating the reactivation or seroreversion of these markers. METHODS The study population consisted of patients met in an AIDS Outpatient Clinic in São Paulo State, Brazil. We included in the analysis all HIV-infected and who underwent at least two positive hepatitis B surface antigen serological testing during clinical follow up, with tests taken six months apart. Patients were tested with commercial kits available for hepatitis B serological markers by microparticle enzyme immunoassay. Clinical variables were collected: age, sex, CD4+ T-cell count, HIV viral load, alanine aminotransferase level, exposure to antiretroviral drugs including lamivudine and/or tenofovir. RESULTS Among 2,242 HIV positive patients, we identified 105 (4.7%) patients with chronic hepatitis B. Follow up time for these patients varied from six months to 20.5 years. All patients underwent antiretroviral therapy during follow-up. Among patients with chronic hepatitis B, 58% were hepatitis B “e” antigen positive at the first assessment. Clearance of hepatitis B surface antigen occurred in 15% (16/105) of patients with chronic hepatitis B, and 50% (8/16) of these patients presented subsequent reactivation or seroreversion of hepatitis B surface antigen. Among hepatitis B “e” antigen positive patients, 57% (35/61) presented clearance of this serologic marker. During clinical follow up, 28.5% (10/35) of those who initially cleared hepatitis B “e” antigen presented seroreversion or reactivation of this marker. CONCLUSIONS Among HIV coinfected patients under antiretroviral therapy, changes of HBV serological markers were frequently observed. These results suggest that frequent monitoring of these serum markers should be recommended.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102017000100219&lng=en&tlng=enHIV infection, Hepatitis B, Chronic, immunologyCoinfectionBiomarkersSeroepidemiologic Studies
collection DOAJ
language English
format Article
sources DOAJ
author Ana Luiza de Castro Conde Toscano
Maria Cássia Mendes Corrêa
spellingShingle Ana Luiza de Castro Conde Toscano
Maria Cássia Mendes Corrêa
Evolution of hepatitis B serological markers in HIV coinfected patients: a case study
Revista de Saúde Pública
HIV infection, Hepatitis B, Chronic, immunology
Coinfection
Biomarkers
Seroepidemiologic Studies
author_facet Ana Luiza de Castro Conde Toscano
Maria Cássia Mendes Corrêa
author_sort Ana Luiza de Castro Conde Toscano
title Evolution of hepatitis B serological markers in HIV coinfected patients: a case study
title_short Evolution of hepatitis B serological markers in HIV coinfected patients: a case study
title_full Evolution of hepatitis B serological markers in HIV coinfected patients: a case study
title_fullStr Evolution of hepatitis B serological markers in HIV coinfected patients: a case study
title_full_unstemmed Evolution of hepatitis B serological markers in HIV coinfected patients: a case study
title_sort evolution of hepatitis b serological markers in hiv coinfected patients: a case study
publisher Universidade de São Paulo
series Revista de Saúde Pública
issn 1518-8787
description ABSTRACT OBJECTIVE To describe the evolution of serological markers among HIV and hepatitis B coinfected patients, with emphasis on evaluating the reactivation or seroreversion of these markers. METHODS The study population consisted of patients met in an AIDS Outpatient Clinic in São Paulo State, Brazil. We included in the analysis all HIV-infected and who underwent at least two positive hepatitis B surface antigen serological testing during clinical follow up, with tests taken six months apart. Patients were tested with commercial kits available for hepatitis B serological markers by microparticle enzyme immunoassay. Clinical variables were collected: age, sex, CD4+ T-cell count, HIV viral load, alanine aminotransferase level, exposure to antiretroviral drugs including lamivudine and/or tenofovir. RESULTS Among 2,242 HIV positive patients, we identified 105 (4.7%) patients with chronic hepatitis B. Follow up time for these patients varied from six months to 20.5 years. All patients underwent antiretroviral therapy during follow-up. Among patients with chronic hepatitis B, 58% were hepatitis B “e” antigen positive at the first assessment. Clearance of hepatitis B surface antigen occurred in 15% (16/105) of patients with chronic hepatitis B, and 50% (8/16) of these patients presented subsequent reactivation or seroreversion of hepatitis B surface antigen. Among hepatitis B “e” antigen positive patients, 57% (35/61) presented clearance of this serologic marker. During clinical follow up, 28.5% (10/35) of those who initially cleared hepatitis B “e” antigen presented seroreversion or reactivation of this marker. CONCLUSIONS Among HIV coinfected patients under antiretroviral therapy, changes of HBV serological markers were frequently observed. These results suggest that frequent monitoring of these serum markers should be recommended.
topic HIV infection, Hepatitis B, Chronic, immunology
Coinfection
Biomarkers
Seroepidemiologic Studies
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102017000100219&lng=en&tlng=en
work_keys_str_mv AT analuizadecastrocondetoscano evolutionofhepatitisbserologicalmarkersinhivcoinfectedpatientsacasestudy
AT mariacassiamendescorrea evolutionofhepatitisbserologicalmarkersinhivcoinfectedpatientsacasestudy
_version_ 1725478282065870848